Phaseline

Targets › MECOM

MECOM (Histone-lysine N-methyltransferase MECOM): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

[Isoform 1]: Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. (UniProt, Q03112)

Open in Phaseline: the race on MECOM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ciusss de L'Est de l'Île de MontréalECT-001-CB
UM171-expanded umbilical cord blood stem cells
MECOMPhase 1Acute Leukemia, High RiskOct 2027

Conditions

Acute Leukemia, High Risk (1)

Modalities

protein or peptide (1)

Companies

Ciusss de L'Est de l'Île de Montréal (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.